Matrix Metalloproteinase-9: Its Interplay with Angiogenic Factors in Inflammatory Bowel Diseases

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2014 May 8

PMID 24803722

Citations 29

Authors

Malgorzata Matusiewicz

Katarzyna Neubauer

Magdalena Mierzchala-Pasierb

Andrzej Gamian

Malgorzata Krzystek-Korpacka

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinase- (MMP-) 9 is one of the main metalloproteinases reported to be involved in extracellular matrix degradation and recently also in triggering of angiogenic switch in the course of inflammatory bowel diseases (IBD). The goal of our studies was to estimate in one experimental setting the levels of MMP-9 in sera of Crohn's Disease (CD) and ulcerative colitis (UC) patients and to evaluate its possible diagnostic potential in comparison with other biochemical markers and selected proinflammatory and angiogenic factors. The study group included 176 subjects (CD = 64, UC = 85, control = 27). Concentrations of serum MMP-9 were significantly higher in active than inactive forms of IBD, being higher in active UC than in active CD. Both in the case of CD and UC serum MMP-9 positively correlated with disease activity, IL-6 levels, platelet and leukocyte count, midkine, and PDGF-BB, as well as in UC with ESR and in CD with CRP, IL-1, and VEGF-A. Diagnostic accuracy of MMP-9 in distinguishing active UC from active CD was 66%, and displayed higher specificity than CRP (79.0% versus 61.6%, resp.). Evaluation of serum MMP-9 concentrations could aid in differentiation of active UC from active CD. MMP-9 correlated better with inflammatory and angiogenic parameters in CD than in UC.

Citing Articles

Bioinformatics analysis reveals potential crosstalk genes and molecular mechanisms between ulcerative colitis and psoriasis.

Luo Q, An M, Wu Y, Wang J, Mao Y, Zhang L Arch Dermatol Res. 2024; 317(1):118.

PMID: 39673621 DOI: 10.1007/s00403-024-03617-6.

Effect of huankuile on colon injury in rats with ulcerative colitis by reducing TNF-α and MMP9.

Wushouer X, Aximujiang K, Kadeer N, Aihemaiti A, Zhong L, Yunusi K Eur J Med Res. 2024; 29(1):102.

PMID: 38321559 PMC: 10845565. DOI: 10.1186/s40001-024-01695-w.

Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease.

Sosna B, Aebisher D, Mysliwiec A, Dynarowicz K, Bartusik-Aebisher D, Oles P Int J Mol Sci. 2024; 25(1).

PMID: 38203373 PMC: 10779120. DOI: 10.3390/ijms25010202.

Crohn's Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review.

Pasternak G, Chrzanowski G, Aebisher D, Mysliwiec A, Dynarowicz K, Bartusik-Aebisher D Life (Basel). 2023; 13(10).

PMID: 37895443 PMC: 10608618. DOI: 10.3390/life13102062.

Biofilm's Impact on Inflammatory Bowel Diseases.

Palandurkar G, Kumar S Cureus. 2023; 15(9):e45510.

PMID: 37868553 PMC: 10585119. DOI: 10.7759/cureus.45510.

References

Pender S, Tickle S, Docherty A, Howie D, Wathen N, MacDonald T . A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 1997; 158(4):1582-90. View

von Lampe B, Barthel B, Coupland S, Riecken E, Rosewicz S . Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000; 47(1):63-73. PMC: 1727961. DOI: 10.1136/gut.47.1.63. View

Castaneda F, Walia B, Vijay-Kumar M, Patel N, Roser S, Kolachala V . Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005; 129(6):1991-2008. DOI: 10.1053/j.gastro.2005.09.017. View

Meijer M, Mieremet-Ooms M, van der Zon A, van Duijn W, van Hogezand R, Sier C . Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis. 2007; 39(8):733-9. DOI: 10.1016/j.dld.2007.05.010. View

Krzystek-Korpacka M, Matusiewicz M, Banas T . [Structure and function of midkine, a novel heparin-binding growth factor]. Postepy Hig Med Dosw (Online). 2006; 60:591-601. View

Visse R, Nagase H . Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8):827-39. DOI: 10.1161/01.RES.0000070112.80711.3D. View

Kim S, Ferry G . Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004; 126(6):1550-60. DOI: 10.1053/j.gastro.2004.03.022. View

Podolsky D . Inflammatory bowel disease. N Engl J Med. 2002; 347(6):417-29. DOI: 10.1056/NEJMra020831. View

Chantrain C, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky D . Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004; 64(5):1675-86. DOI: 10.1158/0008-5472.can-03-0160. View

10.

Manfredi M, Zurakowski D, Rufo P, Walker T, Fox V, Moses M . Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14(8):1091-6. DOI: 10.1002/ibd.20419. View

11.

Danese S . VEGF in inflammatory bowel disease: a master regulator of mucosal immune-driven angiogenesis. Dig Liver Dis. 2008; 40(8):680-3. DOI: 10.1016/j.dld.2008.02.036. View

12.

Kobayashi K, Arimura Y, Goto A, Okahara S, Endo T, Shinomura Y . Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. J Pathol. 2006; 209(3):376-83. DOI: 10.1002/path.1978. View

13.

Sykes A, Bhogal R, Brampton C, Chander C, Whelan C, Parsons M . The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther. 1999; 13(11):1535-42. DOI: 10.1046/j.1365-2036.1999.00633.x. View

14.

Krzystek-Korpacka M, Neubauer K, Matusiewicz M . Circulating midkine in Crohn's disease: clinical implications. Inflamm Bowel Dis. 2009; 16(2):208-15. DOI: 10.1002/ibd.21011. View

15.

Karoui S, Laz S, Serghini M, Bibani N, Boubaker J, Filali A . Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci. 2010; 56(6):1801-5. DOI: 10.1007/s10620-010-1496-7. View

16.

Sternlicht M, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. PMC: 2792593. DOI: 10.1146/annurev.cellbio.17.1.463. View

17.

Tolstanova G, Deng X, Khomenko T, Garg P, Paunovic B, Chen L . Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis. Life Sci. 2010; 88(1-2):74-81. PMC: 9552542. DOI: 10.1016/j.lfs.2010.10.026. View

18.

Pousa I, Mate J, Gisbert J . Angiogenesis in inflammatory bowel disease. Eur J Clin Invest. 2008; 38(2):73-81. DOI: 10.1111/j.1365-2362.2007.01914.x. View

19.

Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K . Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-44. PMC: 2852586. DOI: 10.1038/35036374. View

20.

Rentsch M, Beham A, Schlitt H, Jauch K . Crohn's disease activity index and Vienna classification--is it worthwhile to calculate before surgery?. Dig Surg. 2006; 23(4):241-9. DOI: 10.1159/000095397. View